Final Trade: SBUX, META, XLV and BABA

Key Concepts:

• Starbucks performance (North American comp sales, transaction trends)
• Meta Platforms (investment perspective)
• XLV (Health Care Select Sector SPDR Fund) as a mosaic in the healthcare space
• Pfizer (as a component of XLV)

Final Trade Picks and Analysis:

• Starbucks (Steven): Steven highlights Starbucks, noting that while North American comparable sales were down, they are trending higher, as are transactions. This suggests a potential recovery or positive momentum for the company.
• Meta Platforms (Chairwoman): The Chairwoman discusses Meta Platforms, framing her investment decision with the question: "If I owned none, would I buy it right here?" Her affirmative answer indicates a bullish outlook on Meta's current valuation and future prospects.
• XLV (Sam): Sam focuses on the Health Care Select Sector SPDR Fund (XLV), describing it as a "mosaic in the healthcare space." He finds it "pretty interesting," suggesting potential investment opportunities within the healthcare sector through this ETF.
• Pfizer (Pastiche comment): The discussion briefly touches on Pfizer as a component of XLV. The term "pastiche of pain" is used, possibly implying that Pfizer's recent performance or challenges contribute to a mixed or complex picture within the healthcare sector.

Additional Notes:

• Karen Finerman is being honored by the Harvard Business School.
• The segment is titled "Final Trade," indicating it's a closing segment where investment recommendations are shared.